There is one clinical trial.
Evaluation of the efficacy and safety of Ganovo combined with ritonavir for patients infected with SARS-CoV-2.
Description: Defined as SPO2≤ 93% without oxygen supplementation, PaO2/FiO2 ≤300mmHg or a respiratory rate ≥30 breaths per min without supplemental oxygenMeasure: Rate of composite adverse outcomes Time: 14 days
Description: Clinical recovery was defined as sustained (48 hours) alleviation of illness based on symptom scores (fever, cough, diarrhea, myalgia, dyspnea) all being absent and no evidence for progression (newly-presented dyspnea, SpO2 decline ≥3%, respiratory rate ≥ 24 breaths per min without supplemental oxygen).Measure: Time to recovery Time: 14 days
Description: Rate of no feverMeasure: Rate of no fever Time: 14 days
Description: Rate of no coughMeasure: Rate of no cough Time: 14 days
Description: Rate of no dyspneaMeasure: Rate of no dyspnea Time: 14 days
Description: Rate of no requiring supplemental oxygenMeasure: Rate of no requiring supplemental oxygen Time: 14 days
Description: Rate of undetectable New coronavirus pathogen nucleic acidMeasure: Rate of undetectable New coronavirus pathogen nucleic acid Time: 14 days
Description: Rate of mechanical ventilationMeasure: Rate of mechanical ventilation Time: 14 days
Description: Rate of ICU admissionMeasure: Rate of ICU admission Time: 14 days
Description: Rate of serious adverse eventMeasure: Rate of serious adverse event Time: 14 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports